ET Online|
Research House: JM Financial
Advice: Buy
Stock Price: Rs 441
1-year Target Price: Rs 780
Potential Upside: 76.9%
Comment: Maintain ‘buy’ as increased outsourcing by global retailers, manufacturing operations turnaround, newer revenue streams and expanding US market penetration will support strong top-line growth over three years.
Getty Images
Research House: ICICI Securities
Advice: Buy
Stock Price: Rs 440
1-year Target Price: Rs 600
Potential Upside: 36.4%
Comment: Maintain ‘buy’ rating as portfolio premiumisation, cost rationalisation and operating leverage are expected to support EBITDA margins in the future. Also, a well-balanced distribution channel and focus on improving service business are key strongholds.
Getty Images
Research House: Asian Markets Securities
Advice: Buy
Stock Price: Rs 143
1-year Target Price: Rs 185
Potential Upside: 29.4%
Comment: Initiate with ‘buy’ due to likely improvement in margins and return ratios in the future. Recovery in home textiles business, flooring segment expansion and net debt-free target by 2026-27 are key positives.
Getty Images
Research House: Anand Rathi
Advice: Buy
Stock Price: Rs 756
1-year Target Price: Rs 950
Potential Upside: 25.7%
Comment: Initiate with ‘buy’ due to expectations of a good performance, aided by capacity expansion, product launches and better margins. Also, acquisition synergies, strong capex, robust R&D and geographical diversification are key positives.
Getty Images
Research House: HDFC Securities
Advice: Buy
Stock Price: Rs 2,180
1-year Target Price: Rs 2,639
Potential Upside: 21.1%
Comment: Rate ‘buy’ due to client loyalty, design differentiation in premium offerings and likely strong pre-sales growth. Valuation support, free cash-flow generation, likely deleveraging are near-term catalysts for further rerating.
Getty Images
Research House: Motilal Oswal
Advice: Buy
Stock Price: Rs 2,214
1-year Target Price: Rs 2,650
Potential Upside: 19.7%
Comment: Initiate with ‘buy’ due to expanded product offerings in major therapies, capitalising on leverage, gradual increase in share of chronic therapies, improving MR productivity, and footprint expansion in tier-1 cities.
Getty Images
Read more on
